retatrutide weight loss trial results Results: How Much Can You Lose & How Quick? ✨ Big news in the

Sarcopenic obesity, which combines obesity and sarcopenia, is concerning and is associated with reduced quality of life and elevated risk of falls, cardiovascular disease, and mortality

The pace of growth is slowed to about 1.3 to 1.5 percent right now

However, CMS clarified in a memo dated March 20, 2024, that anti-obesity medications that receive FDA approval for an additional medically accepted indication can be considered a Part D drug for that specific use. As of August 19, 2024, the only GLP-1 RA this applies to is Wegovy, which, in addition to its obesity indication, is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight

doi: 10.1093/jn/nxaa049, 101

Pain and comfort: Pen needles tend to be shorter and finer than standard insulin syringe needles

This is because shots enable the body to absorb vitamin B12 without going through the digestive system